- Differential Diagnosis
- Try building your search one term at a time, and be as specific as you can! Search term example: "chronic cough".
- Do not enter multiple findings such as "anemia, chronic cough, weight loss, vomiting" all at the same time.
- After selecting your term from the search results a list of possible diagnoses will be generated. If the list is too long, you will be able to narrow it down by entering additional terms.
- Do not enter values such as "heart rhythm 110" or "sodium 125", instead use "tachycardia" or "hyponatremia".
Drug Information for CIMETIDINE HYDROCHLORIDE ORAL SOLUTION0506 (TEVA PHARMACEUTICALS USA): INDICATIONS AND USAGE
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- HOW SUPPLIED
- External Links Related to CIMETIDINE HYDROCHLORIDE ORAL SOLUTION0506 (TEVA PHARMACEUTICALS USA)
Cimetidine hydrochloride oral solution is indicated in:
1) Short-term treatment of active duodenal ulcer
Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION - Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine.
2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer
Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years.
3) Short-term treatment of active benign gastric ulcer
There is no information concerning usefulness of treatment periods of longer than 8 weeks.
4) Erosive gastroesophageal reflux disease (GERD)
Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for 12 weeks for healing of lesions and control of symptoms. The use of cimetidine beyond 12 weeks has not been established (see DOSAGE AND ADMINISTRATION-GERD).
5) The treatment of pathological hypersecretory conditions
(i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas).
- Drug Information Provided by National Library of Medicine (NLM).